Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

RHHBY has been the subject of a number of research ... Hancock Whitney Corp now owns 23,516 shares of the company’s stock valued at $820,000 after acquiring an additional 1,496 shares during ...

BofA lowered the firm’s price target on Illumina (ILMN) to $90 from $110 and keeps an Underperform rating on the shares. Shares have fallen 25% ...

If you are looking for an AI stock that is more promising than RHHBY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI ...

Assess today's live Roche Holding Ltd DRC (RHHBY) share price, performance and insights using our live OTC Markets: RHHBY stock exchange data. Analyse the historical data and Roche Holding Ltd DRC ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

The tablet can be swallowed whole or dispersed in water. PFE, NVS and ABBV have a Zacks Rank #3 (Hold) each, while Sanofi and RHHBY have a Zacks Rank #4 (Sell) each. You can see the complete list ...

Novartis announced a definitive agreement to acquire private biotech Anthos Therapeutics, which will strengthen its cardiovascular pipeline by adding abelacimab, the latter’s lead pipeline ...

Novartis announced a definitive agreement to acquire private biotech Anthos Therapeutics, which will strengthen its cardiovascular pipeline by adding abelacimab, the latter’s lead pipeline candidate ...